Please fill out the form below and we will gladly respond as soon as possible.
A recent case report describes a rare but serious complication in a patient with metastatic synovial sarcoma of the lung—highlighting the importance of infection monitoring following thoracic surgery. The case focuses on pleural aspergillosis, an uncommon fungal infection that can occur in immunocompromised patients, particularly after lung surgery. A Complex Clinical Course A 28-year-old patient […]
A recent case report describes an extremely rare solitary fibrous tumor (SFT) occurring in the maxilla (upper jaw), highlighting the importance of accurate diagnosis in rare soft tissue tumors. Although SFT is different from synovial sarcoma, both are rare mesenchymal tumors that can present similarly, making diagnosis dependent on specialized testing. A Rare Presentation A […]
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by science, but by financial viability. As Kristen Hege, former SVP at Bristol Myers Squibb, explains:“Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s […]
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over 20 investigational therapies aimed at improving treatment options for this rare cancer. Although synovial sarcoma remains difficult to treat, the growing number of clinical trials reflects increasing research investment and scientific focus on this disease. […]
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have faced a structural disadvantage. Fewer treatment options. Fewer clinical trials. Less research funding. Now a new law in the United Kingdom aims to change that. The Rare Cancers Bill, introduced by Dr Scott Arthur MP, […]
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option. A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed […]
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for its second community webinar—an evening focused on progress, partnership, and hope. The full webinar recording is available to watch below: The webinar was moderated by Nathan Imperiale, Chairman of the Board, and featured: Highlights Foundation […]
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For years, research and therapeutic development have focused on how this fusion interacts with the SWI/SNF chromatin remodeling complex, believed to play a central role in tumor growth. However, newly published research challenges that long-standing assumption […]
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023 and is projected to reach $1.6 billion by 2031. While market reports focus on financial projections, they often reflect broader trends in research, drug development, and clinical trial activity. For the synovial sarcoma community, this […]
Join the Synovial Sarcoma Foundation for a live, one-hour webinar focused on where synovial sarcoma research is heading and what that progress means for patients and families today. The conversation will bring together real patient experiences with insights from researchers and clinicians leading efforts in synovial sarcoma. We’ll discuss emerging research, areas of real momentum, […]